You Searched For "Mylan" and got 20 results
Sort By:
3 mins read
The biotech merger drama continues as Mylan rejects Teva's buyout offer
"After thorough consideration, Mylan's Board unanimously determined that Teva's proposal grossly un…
Akin Oyedele  Â
4 mins read
Mylan and the DOJ can't seem to get on the same page these days
"It's hard to understand why the Justice Department won't testify about allegedly hundreds of mill…
Lydia Ramsey  Â
3 mins read
Investigations are piling up at Mylan
But that's not the only legal matter Mylan's facing. The company's also under investigation generic…
Lydia Ramsey  Â
3 mins read
Perrigo plunges after Mylan bid flops
Mylan CEO Heather Bresch commented, "Mylan's focused approach to organic and inorganic growth has d…
Jonathan Marino  Â
2 mins read
Mylan is recalling EpiPens in the US
Mylan was called out in August 2016 for raising the price of the EpiPen to $608.61 from $93.88 over…
Lydia Ramsey  Â
2 mins read
Mylan skyrockets after securing a merger with Pfizer's off-patent drug unit
The new company will be rebranded and renamed, and Heather Bresch - the chief executive officer of …
Daniel Strauss  Â
2 mins read
Mylan quietly made an acquisition for almost half a billion dollars in July that it didn't tell investors about right away
Mylan missed on its earnings last week, and its stock dropped as much as 7% after markets. Mylan sa…
Lydia Ramsey  Â
2 mins read
$11 billion drugmaker Mylan and US drug giant Pfizer are teaming up to reshape Mylan's business. 3 tough questions from Wall Street analyst show the challenging road ahead.
"This is about enhancing every aspect of our organization, starting with the Board of Directors, st…
Emma Court  Â
5 mins read
Mylan's decision to make a cheaper, generic EpiPen 'baffles' experts
"I wonder whether their generic will be fully substitutable by pharmacists, a question which may de…
Lydia Ramsey  Â
3 mins read
The FDA just approved a generic EpiPen, and analysts think it has the potential to upend Mylan's hold on the market
In May 2017, the FDA said that there was a shortage of EpiPens in the US, because of issues with th…
Lydia Ramsey  Â
2 mins read
Mylan says it won't testify at a Senate hearing about the EpiPen
"It's hard to understand why the Justice Department won't testify about allegedly hundreds of mill…
Lydia Ramsey  Â
2 mins read
Lawmakers are accusing Mylan of overcharging Medicaid for the EpiPen - and the stock is tanking
In the face of outrage over the price of the EpiPen, Mylan said on Monday that it will make a…
Lydia Ramsey  Â
1 min read
Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall
New Delhi, Jan 9 () Amid the voluntary recall of Nizatidine API by Mylan, Solara Active Pharma Scie…
PTI Â Â
1 min read
EpiPen-maker Mylan misses on Q3 earnings
Excluding items, such as the $465 million Department of Justice settlement expense, Mylan said it h…
Lydia Ramsey,Reuters  Â
1 min read
Wall Street analysts are throwing shade at Pfizer's deal with Mylan, saying it will hurt profits through 2020
Several Wall Street analysts noted that the company's decision to merge Upjohn - Pfizer's off-paten…
Ben Winck  Â
2 mins read
The committee that brought in Martin Shkreli and Valeant to testify is now going after Mylan
"Mylan has a virtual monopoly over the epinephrine auto-injector market. A national dependence on a…
Lydia Ramsey  Â
3 mins read
Here's what to expect when the CEO of EpiPen-maker Mylan testifies before Congress
To fend off public outrage over the EpiPen's cost, Mylan recently raised its copay-coupon system to…
Lydia Ramsey  Â
4 mins read
Here's why it's ridiculously tempting for the CEO of Mylan to keep hiking the price of EpiPen
Another way the company could get to $6 per share, is to increase EpiPen's 2015 sales - at the curr…
Linette Lopez  Â
6 mins read
Shares of drugmaker Perrigo are going insane after a buyout offer from Mylan
The Mylan Board believes that continuity of our management team, with its successful track record o…
Myles Udland  Â
1 min read
Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licence
New Delhi, Nov 27 () Biotechnology major Biocon on Wednesday said that US health regulator has appr…